Drugs (2022) 82:611 https://doi.org/10.1007/s40265-022-01712-4 CORREC TION Young‑A Heo Published online: 30 March 2022 © Springer Nature 2022 Correction to: Drugs (2022) 82:341–348 or exceeds the permitted use, you will need to obtain per- https:// doi. org/ 10. 1007/ s40265- 022- 01678-3 mission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ The article Efgartigimod: First Approval, written by Young- by- nc/4. 0/. A Heo, was originally published electronically in Springer- Link on 18 February 2022 without open access. After publi- The original article has been corrected. cation volume 82, issue 3, pages 341–342, argenx requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by argenx. This article is licensed under a Creative Com- Open Access This article is licensed under a Creative Commons Attri- mons Attribution-NonCommercial 4.0 International License, bution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction which permits any non-commercial use, sharing, adaptation, in any medium or format, as long as you give appropriate credit to the distribution and reproduction in any medium or format, as original author(s) and the source, provide a link to the Creative Com- long as you give appropriate credit to the original author(s) mons licence, and indicate if changes were made. The images or other and the source, provide a link to the Creative Commons third party material in this article are included in the article’s...